Following a single infusion of CD19-targeting CAR T cells, five patients with SLE showed reduction in disease activity and disease markers; long-term follow-up of these patients and larger trials are now key priorities.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Arbuckle, M. R. et al. N. Engl. J. Med. 349, 1526–1533 (2003).
Furie, R. et al. Arthritis Rheum. 63, 3918–3930 (2011).
Furie, R. A. et al. Ann. Rheum. Dis. 81, 100–107 (2022).
Mackensen, A. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02017-5 (2022).
Mei, H. E. et al. Blood 125, 1739–1748 (2015).
Pisetsky, D. S. & Lipsky, P. E. Nat. Rev. Rheumatol. 16, 565–579 (2020).
Kiefer, K. et al. Immunol. Cell Biol. 90, 498–504 (2012).
Barrat, F. J. et al. J. Exp. Med. 202, 1131–1139 (2005).
Catalina, M. D. et al. JCI Insight 5, e140380 (2020).
DeZern, A. E. et al. Medicine 90, 89–98 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Disclosures: UCB, scientific advisor; UCB, investigator-initiated grant; Bristol Myers Squibb, scientific advisor; SciRhom GmbH, scientific advisor.
Rights and permissions
About this article
Cite this article
Salmon, J.E. Arming T cells against B cells in systemic lupus erythematosus. Nat Med 28, 2009–2010 (2022). https://doi.org/10.1038/s41591-022-02024-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02024-6